Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications

Area of Science:

• Cardiology
• Endocrinology
• Diabetology

Background:

• Diastolic heart failure (DHF) presents with heart failure symptoms but preserved left ventricular systolic function.
• Approximately 40% of chronic heart failure (CHF) patients have DHF.
• Diabetes mellitus is a significant risk factor for DHF, with diastolic dysfunction observed in 40% of diabetic patients, correlating with poor glycemic control.

Purpose of the Study:

• To review the mechanisms and management of diastolic dysfunction in patients with diabetes mellitus.
• To highlight the limited specific research on DHF management compared to systolic heart failure.
• To discuss the findings of the CHARM-Preserved trial regarding DHF treatment.

Main Methods:

• Review of existing literature on diastolic dysfunction in diabetes mellitus.
• Analysis of the CHARM-Preserved trial data for DHF outcomes.
• Discussion of current pharmacologic treatments for heart failure applied to DHF.

Main Results:

• Multiple proposed mechanisms link diabetes to diastolic dysfunction, including metabolic, structural, and hormonal changes.
• The CHARM-Preserved trial demonstrated that candesartan (an angiotensin receptor blocker) reduced CHF hospital admissions in DHF patients but not cardiovascular death.
• Current DHF management often mirrors systolic heart failure treatment, including diuretics, nitrates, ACE inhibitors, ARBs, aldosterone antagonists, and beta-blockers.

Conclusions:

• Diastolic dysfunction is prevalent in diabetic patients and multifactorial.
• While ARBs show some benefit in DHF hospitalizations, specific antihyperglycemic strategies for DHF remain undetermined.
• Further research is needed to establish optimal glycemic control and antihyperglycemic regimens for diabetic patients with DHF.